Smith & Nephew PLC (SNN) is currently not a strong buy for a beginner investor with a long-term strategy. While the company has shown solid financial performance and growth in its latest quarter, the technical indicators suggest a bearish trend, and hedge funds are actively selling the stock. Additionally, there are limited near-term catalysts, and analysts' ratings are mixed, with no strong upward momentum in price targets. For a long-term investor, it may be better to wait for a more favorable entry point or clearer positive signals.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 29.946, showing no clear signal. The stock is trading below its pivot support level (S1: 34.654), suggesting potential further downside. Moving averages are converging, indicating indecision in the market.

Smith & Nephew showcased innovative surgical technologies, including the CORI Surgical System and REGENETEN Bioinductive Implant, which address significant market opportunities. The company reported strong Q4 revenue growth of 8.3% YoY and increased profit before tax in fiscal 2025.
Hedge funds are selling the stock, with a 225.80% increase in selling activity over the last quarter. Analysts have mixed ratings, with some downgrades citing material risks and limited near-term catalysts. The stock is experiencing bearish technical momentum.
Smith & Nephew reported Q4 revenue of $1.7 billion, an 8.3% YoY growth, driven by strong performance in the Orthopaedics division. Fiscal 2025 profit before tax rose to $779 million, with EPS increasing to 71.6 cents, reflecting strong market performance.
Analysts' ratings are mixed. Canaccord raised the price target to $35 with a Hold rating, citing solid quarterly performance. Barclays raised the price target slightly but maintained an Equal Weight rating. RBC downgraded the stock, citing material risks and limited catalysts, while Morgan Stanley lowered its price target but maintained an Overweight rating.